WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will release its second-quarter 2025 financial results after market close on Thursday, August 14, followed by a 4:30 p.m. ET conference call to discuss recent regulatory developments, strategic plans, and operational priorities.
The clinical-stage biopharmaceutical company is advancing therapies from its NMDA platform for conditions including suicidal depression, chronic pain, and PTSD. Its lead candidates, NRX-100 (IV ketamine) and NRX-101 (oral D-cycloserine/lurasidone), have both received expedited FDA designations, with an NDA for NRX-101 planned under Accelerated Approval.
NRx has also filed an ANDA and begun the NDA process for NRX-100, supported by clinical trial data from U.S. and French government studies.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.